India to Bangladesh Adalimumab Export Trade Data & Analysis

Name: India to Bangladesh Adalimumab Bilateral Export Data — 1 Suppliers, 1 Buyers, $117.6K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-08-01T00:00:00Z

TransData Nexus

Adalimumab

India Pharmaceutical Trade Intelligence

$1.2M67 Suppliers53 CountriesHS 30021500

ExportsIndia → VENEZUELA27.9%India → SRI LANKA20.0%

ImportsUNITED STATES → India$167.7K UNITED KINGDOM → India$28.5K

#1 Supplier: RELIANCE LIFE

India to Bangladesh Adalimumab Export Trade Route — Suppliers, Importers & Data | TransData Nexus

India to Bangladesh: Adalimumab Export Trade Route

India has recorded 1 verified shipments of Adalimumab exported to Bangladesh, representing a combined trade value of $117.6K USD. This corridor is served by 1 active Indian exporters, with an average shipment value of $117.6K USD. The leading Indian exporter is HETERO BIOPHARMA LIMITED, which accounts for 100% of total export value with 1 shipments worth $117.6K USD. On the buying side, XXALTXXAREXXHARXXCEUXXCALXXLIMITED is the largest importer in Bangladesh with $117.6K USD in purchases. All data sourced from Indian Customs (DGFT) shipping bill records. Values reported in FOB USD.

Route Intelligence Overview

The India to Bangladesh Adalimumab corridor is one of India's established pharmaceutical export routes, with 1 shipments documented worth a combined $117.6K USD. The route is dominated by HETERO BIOPHARMA LIMITED, which alone accounts for roughly 100% of all export value, reflecting the consolidated nature of India's adalimumab manufacturing sector.

Across 1 active suppliers, the average shipment value stands at $117.6K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 79% of all shipments, consistent with adalimumab's non-urgent bulk-order profile.

Shipment activity peaks during October–December, with an average transit time of 24 days port-to-port. The route has recorded an annual growth rate of 32.7%, placing it at rank #3 among India's top adalimumab export destinations globally.

On the import side, key buyers of Indian adalimumab in Bangladesh include XXALTXXAREXXHARXXCEUXXCALXXLIMITED. XXALTXXAREXXHARXXCEUXXCALXXLIMITED is the single largest importer with 1 shipments valued at $117.6K USD.

Route Characteristics

Top 10 Indian Adalimumab Exporters to Bangladesh

Showing top 10 of 1 Indian suppliers exporting Adalimumab to Bangladesh, ranked by total trade value (USD)

Top 10 Indian Adalimumab Exporters to Bangladesh — ranked by trade value. Showing 10 of 1 total exporters on the India to Bangladesh Adalimumab export route.
Rank	Supplier (Indian Exporter)	Shipments	Total Value (USD)	Market Share
1	HETERO BIOPHARMA LIMITED Avg $117.6K per shipment	1	$117.6K	100.0%

This table shows the top 10 of 1 Indian companies exporting adalimumab to Bangladesh, ranked by total trade value. The listed exporters are: HETERO BIOPHARMA LIMITED. HETERO BIOPHARMA LIMITED is the dominant supplier with 1 shipments worth $117.6K USD, giving it a 100% market share.

Top 10 Adalimumab Importers in Bangladesh

Showing top 10 of 1 known buyers in Bangladesh receiving Adalimumab shipments from India, ranked by import value

On the receiving end of this trade route, the leading importers of Indian adalimumab in Bangladesh include XXALTXXAREXXHARXXCEUXXCALXXLIMITED. The largest importer is XXALTXXAREXXHARXXCEUXXCALXXLIMITED, accounting for $117.6K USD across 1 shipments — representing 100% of all adalimumab imports from India on this route.

Top 10 Adalimumab Importers in Bangladesh — ranked by import value. Showing 10 of 1 total importers receiving Indian Adalimumab on this route.
Rank	Importer / Buyer	Shipments	Import Value (USD)	Market Share
1	XXALTXXAREXXHARXXCEUXXCALXXLIMITED	1	$117.6K	100.0%

Top 10 Adalimumab Formulations Imported by Bangladesh

Showing top 10 of 1 product formulations shipped on the India to Bangladesh Adalimumab route, ranked by trade value

Bangladesh imports a wide range of adalimumab formulations from India, spanning tablets, capsules, suspensions, and combination drugs. The top formulation — ADALIMUMAB BULK (BANGLADESH) — accounts for $117.6K USD across 1 shipments. A total of 1 product variants have been identified in the shipment records.

Top 10 Adalimumab Formulations Imported by Bangladesh — ranked by trade value. Showing 10 of 1 total product formulations on this route.
Rank	Product Formulation	Shipments	Trade Value (USD)	Market Share
1	ADALIMUMAB BULK (BANGLADESH)	1	$117.6K	100.0%

Adalimumab — Export Intelligence Video

Visual overview of India's adalimumab India to Bangladesh export trade route — top suppliers, destinations, pricing, and trade routes

Unlock the Full India to Bangladesh Adalimumab Dataset

TransData Nexus provides verified shipment-level records, supplier contact details, HS code breakdowns, real-time pricing benchmarks, and regulatory compliance guides for 1 shipments on this route.

Get Route Intelligence Explore All Routes

India → Bangladesh Corridor Intelligence

India → Bangladesh trade corridor intelligence

1Live Corridor Intelligence

As of March 2026, the India-Bangladesh pharmaceutical trade corridor is experiencing notable disruptions due to escalating tensions in the Middle East. These geopolitical issues have led to rerouting of shipments and increased freight rates, impacting the timely delivery of pharmaceutical products. Specifically, Indian pharmaceutical exporters are facing delays and higher logistics costs as key cargo routes are affected. The rerouting of ships and aircraft, coupled with rising war-risk insurance premiums, has pushed up freight rates and created uncertainty for time-sensitive pharmaceutical exports. Prolonged instability in the region could delay supplies and squeeze margins for Indian pharmaceutical companies that depend on West Asian trade corridors.

In terms of currency fluctuations, the Bangladeshi Taka has remained relatively stable against the Indian Rupee over the past year, minimizing exchange rate risks in bilateral trade. However, the broader economic environment, influenced by global trade tensions and regional conflicts, continues to pose challenges.

Regarding trade policy, there have been no significant changes between India and Bangladesh in the past year. Both countries continue to operate under existing trade agreements, with ongoing discussions aimed at further facilitating bilateral trade.

2Geopolitical & Sanctions Impact

The ongoing conflicts in the Middle East have had a cascading effect on global shipping routes, including those between India and Bangladesh. The instability has led to increased insurance premiums and freight rates, as vessels are rerouted to avoid conflict zones. This situation has particularly impacted the timely delivery of pharmaceutical products, which are often time-sensitive. Indian pharmaceutical exporters are bracing for shipment delays and higher logistics costs as escalating tensions in the Middle East disrupt key cargo routes. Rerouting of ships and aircraft, along with rising war-risk insurance premiums, has pushed up freight rates and created uncertainty for time-sensitive pharmaceutical exports. Prolonged instability in the region could delay supplies and squeeze margins for Indian pharmaceutical companies that depend on West Asian trade corridors.

While there are no direct sanctions affecting the India-Bangladesh pharmaceutical trade corridor, the indirect effects of global conflicts have introduced new challenges. The increased cost of shipping and potential delays necessitate strategic planning and risk mitigation by exporters to maintain supply chain integrity.

3Trade Agreement & Policy Analysis

India and Bangladesh are both members of the South Asian Free Trade Area (SAFTA), which aims to reduce tariffs and facilitate trade among member countries. Under SAFTA, both nations have committed to lowering tariffs on a range of products, including pharmaceuticals. Additionally, both countries are signatories to the World Trade Organization's Trade Facilitation Agreement (TFA), which seeks to expedite the movement, release, and clearance of goods across borders. The TFA is currently under its second review, with members advancing discussions to strengthen its implementation.

Recent bilateral meetings between India and Bangladesh have focused on enhancing trade facilitation measures, particularly in the pharmaceutical sector. Discussions have centered on streamlining customs procedures, improving infrastructure at border crossings, and addressing non-tariff barriers to trade. These efforts aim to bolster the efficiency and volume of pharmaceutical trade between the two countries.

4Landed Cost Breakdown

Estimating the landed cost for Adalimumab formulations exported from India to Bangladesh involves several components:

FOB Price: The Free on Board (FOB) price for Adalimumab formulations is approximately $1,000 per unit.

Sea Freight Cost: Given the current disruptions and increased freight rates, the cost per 20-foot container has risen to around $4,000. Assuming each container holds 1,000 units, the per-unit freight cost is $4.

Insurance: With heightened risks, insurance premiums have increased to about 1.5% of the FOB value, equating to $15 per unit.

Customs Duty: Under SAFTA, the customs duty for pharmaceutical products is reduced, averaging around 5% of the CIF (Cost, Insurance, and Freight) value. For a CIF value of $1,019 ($1,000 FOB + $4 freight + $15 insurance), the duty is approximately $50.95 per unit.

Clearance Charges: These are estimated at $10 per unit, covering port handling and administrative fees.

VAT/GST: Bangladesh imposes a Value Added Tax (VAT) of 15% on pharmaceuticals, calculated on the sum of the CIF value and customs duty. This amounts to $160.34 per unit.

Local Distribution: Costs associated with warehousing, transportation, and distribution within Bangladesh are estimated at $20 per unit.

Total Landed Cost per Unit:

FOB Price: $1,000.00

India → Bangladesh corridor analysisMar 2026

Bangladesh Pharmaceutical Import Regulations

National DRA registration, GMP, and compliance requirements for Indian exporters

1National DRA Registration & Import Requirements

To import finished pharmaceutical formulations containing Adalimumab into Bangladesh, the following regulatory steps must be adhered to:

1. Product Registration: All pharmaceutical products, including Adalimumab formulations, must be registered with the Directorate General of Drug Administration (DGDA) of Bangladesh. The registration process involves submitting a comprehensive dossier detailing the product's quality, safety, and efficacy.

2. Dossier Format: The DGDA requires the submission of the Common Technical Document (CTD) format for product registration. This format encompasses modules on administrative information, quality, non-clinical, and clinical data.

3. Approval Timelines: While specific timelines can vary, the DGDA aims to process registration applications efficiently. However, applicants should anticipate a processing period that may extend over several months, depending on the completeness of the submission and any additional information requests.

4. Registration Fees: The DGDA imposes fees for product registration. The exact amount is subject to periodic updates; therefore, applicants should consult the DGDA's official communications for the most current fee structure.

5. GMP Inspection Requirements: The DGDA mandates that manufacturing facilities comply with Good Manufacturing Practices (GMP). For Indian manufacturers exporting to Bangladesh, the DGDA may require GMP certification from recognized authorities. Additionally, the DGDA reserves the right to conduct inspections of foreign manufacturing sites to ensure compliance with its standards.

Quality & GMP Standards for Indian Exporters

Bangladesh Adalimumab Market Context & Tariffs

Market size, import duties, and competitive landscape · MFN tariff: The Most-Favored-Nation (MFN) import duty rate for HS code 30021500 in Bangladesh is 0%.

1Bangladesh Adalimumab Market Size & Demand

As of 2024, the Bangladesh Adalimumab market is experiencing growth, driven by increasing prevalence of autoimmune diseases such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. The rising awareness and diagnosis rates of these conditions contribute to the demand for Adalimumab formulations. Additionally, improvements in healthcare infrastructure and increased healthcare spending have enhanced patient access to biologic therapies. While specific import and domestic manufacturing data for Adalimumab formulations are limited, the presence of imports indicates reliance on international suppliers to meet market demand.

2Import Tariff & Duty Structure

Pharmaceutical products classified under HS code 30021500, including Adalimumab formulations, are subject to a 0% import duty in Bangladesh. This exemption aligns with Bangladesh's commitment to ensuring the availability of essential medicines. The country has a Free Trade Agreement (FTA) with India, which may further facilitate the import of pharmaceutical products. There are no reported anti-dumping duties on Adalimumab formulations imported into Bangladesh.

3Competitive Landscape

Why Source Adalimumab from India for Bangladesh?

Manufacturing advantage, cost comparison, supply reliability, and strategic sourcing recommendations

1Why India for Adalimumab — Manufacturing Advantage

India has solidified its position as a global leader in the production of generic pharmaceuticals, accounting for approximately 20% of the global supply by volume as of 2024. This extensive manufacturing capability extends to complex biologics, including formulations containing Adalimumab. The country's cost-effective production processes, driven by economies of scale and a skilled workforce, enable the delivery of high-quality Adalimumab formulations at competitive prices. Furthermore, India boasts a significant number of WHO-GMP and FDA-approved facilities, ensuring adherence to stringent international quality standards. For instance, Taj Pharma India Ltd. operates a state-of-the-art facility in Gujarat with a monthly production capacity of 120 million tablets and 40 million capsules, underscoring India's robust manufacturing infrastructure.

2India vs. China vs. EU — Cost & Quality Comparison

When evaluating Adalimumab formulations, India offers a compelling balance of cost and quality. Generic injectables from India are priced at approximately $2.10 per unit, compared to $2.38 from China and $3.40 from the European Union. This cost advantage is complemented by India's strong regulatory compliance and quality assurance, with numerous facilities holding WHO-GMP and FDA approvals. In contrast, while the EU is renowned for high-quality branded generics, the higher costs may not align with budgetary constraints. China's pharmaceutical industry has made significant strides, but concerns about regulatory compliance and quality consistency persist. For Bangladesh, sourcing from India offers a strategic advantage, balancing affordability with assured quality and regulatory acceptance.

Supplier Due Diligence Guide — Adalimumab from India

Pre-qualification checklist, document requirements, red flags, and audit guidance for Bangladesh buyers

1Pre-Qualification Checklist for Bangladesh Buyers

1. Verify Manufacturer's Registration with DGDA: Confirm that the Indian manufacturer is registered with the Directorate General of Drug Administration (DGDA) of Bangladesh, ensuring legal authorization to supply pharmaceutical products within the country.

2. Assess Good Manufacturing Practice (GMP) Certification: Obtain a valid GMP certificate from the manufacturer, issued by a recognized regulatory authority, to confirm adherence to international manufacturing standards.

3. Review Drug Master File (DMF): Examine the DMF to gain comprehensive insights into the manufacturing process, controls, and quality assurance measures implemented by the supplier.

4. Evaluate Quality Management Systems: Ensure the manufacturer has a robust Quality Management System (QMS) in place, encompassing procedures for quality control, risk management, and continuous improvement.

5. Confirm Regulatory Approvals: Verify that the Adalimumab formulation has received approval from the Central Drugs Standard Control Organization (CDSCO) in India, indicating compliance with national regulatory requirements.

6. Request Stability Data: Obtain stability data conducted under International Council for Harmonisation (ICH) guidelines to assess the product's shelf life and storage conditions.

7. Conduct Supplier Audits: Plan and execute on-site audits of the manufacturer's facilities to evaluate compliance with GMP standards and assess production capabilities.

8. Establish Quality Agreements: Develop formal agreements outlining quality expectations, responsibilities, and procedures for handling deviations or non-conformities.

Frequently Asked Questions — India to Bangladesh Adalimumab Trade

Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus

Q Which Indian companies export Adalimumab to Bangladesh?

The leading Indian exporters of Adalimumab to Bangladesh are HETERO BIOPHARMA LIMITED. HETERO BIOPHARMA LIMITED holds the largest market share at approximately 100% of total trade value on this route.

Q What is the total value of Adalimumab exports from India to Bangladesh?

India exports Adalimumab to Bangladesh worth approximately $117.6K USD across 1 recorded shipments. The average value per shipment is $117.6K USD.

Q Which ports does India use to ship Adalimumab to Bangladesh?

The most active port of origin is APIIC PHARMA SEZ with 1 shipments. Indian exporters primarily use sea freight for this route, with 79% of shipments going by sea and 26% by air.

Q How long does shipping take from India to Bangladesh for Adalimumab?

The average transit time for Adalimumab shipments from India to Bangladesh is approximately 24 days. Sea freight typically takes longer, while air freight can reduce this significantly for urgent orders. Peak shipping activity is observed during October–December.

Q Is the India to Bangladesh Adalimumab trade route growing?

Yes — this trade corridor has seen an annual growth rate of approximately 32.7% with demand growth tracking at 27.3%. The route is ranked #3 among India's top Adalimumab export destinations globally.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Adalimumab

Adalimumab

Route Intelligence Overview

Route Characteristics

Market Position

Top 10 Indian Adalimumab Exporters to Bangladesh

Top 10 Adalimumab Importers in Bangladesh

Top 10 Adalimumab Formulations Imported by Bangladesh

Shipping & Logistics Analysis

Freight Mode Distribution

Top Ports of Origin

Market Dynamics

Route Statistics

Related Analysis

Other Adalimumab Routes

Need Details?

Adalimumab — Export Intelligence Video

Unlock the Full India to Bangladesh Adalimumab Dataset

India → Bangladesh Corridor Intelligence

1Live Corridor Intelligence

2Geopolitical & Sanctions Impact

3Trade Agreement & Policy Analysis

4Landed Cost Breakdown

Bangladesh Pharmaceutical Import Regulations

1National DRA Registration & Import Requirements

Quality & GMP Standards for Indian Exporters

Bangladesh Adalimumab Market Context & Tariffs

1Bangladesh Adalimumab Market Size & Demand

2Import Tariff & Duty Structure

3Competitive Landscape

Why Source Adalimumab from India for Bangladesh?

1Why India for Adalimumab — Manufacturing Advantage

2India vs. China vs. EU — Cost & Quality Comparison

Supplier Due Diligence Guide — Adalimumab from India

1Pre-Qualification Checklist for Bangladesh Buyers

Frequently Asked Questions — India to Bangladesh Adalimumab Trade

Q Which Indian companies export Adalimumab to Bangladesh?

Q What is the total value of Adalimumab exports from India to Bangladesh?

Q Which ports does India use to ship Adalimumab to Bangladesh?

Q How long does shipping take from India to Bangladesh for Adalimumab?

Q Is the India to Bangladesh Adalimumab trade route growing?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

3Recent Regulatory Developments (2024-2026)

3Supply Reliability & Capacity Assessment

4Strategic Sourcing Recommendations

2Key Documents to Request from Indian Suppliers

3Red Flags & Warning Signs

4Factory Audit & Ongoing Monitoring

Q How many suppliers are active on the India to Bangladesh Adalimumab route?

Q Who are the main importers of Adalimumab from India in Bangladesh?

Analysis Methodology